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Background: MicroRNAs have recently emerged as key regulators of cancers, miR-329 located on 14q32.31 is one
of down-regulated miRNAs in glioma, but the function and molecular mechanisms of miR-329 in determining the
malignant phenotype of human glioma are elusive. This study therefore was conducted to investigate the role of
miR-329 in biological behaviors of human glioma LN18 and T98G cell lines and its molecular mechanisms.
Methods: Nine patients with GBM were analyzed for the expression of miR-329 by quantitative RT–PCR. MiR-329
overexpression was established by transfecting miR-329 precursor into LN18 and T98G cells, and its effects on cell
proliferation were studied using MTT assay, anchorage-independent growth ability assay, colony formation assays,
Bromodeoxyuridine labeling and immunofluorescence.
The effects of miR-329 on cell cycle were studied by flow cytometry. The target of miR-329 was determined by
luciferase assays. The regulation of miR-329 on Akt pathway was determined by western blot.
Results: The E2F1 was identified as the target of miR-329. Overexpression of miR-329 blocked G1/S transition in
LN18 and T98G cell lines, dramatically suppressed cell proliferation and the ability of colony formation. MiR-329
significantly decreased the phosphorylation levels of intracellular kinases Akt and expression of cyclin D1, but the
expression of p21 was upregulated, cell growth was suppressed by inhibiting E2F1-mediated Akt pathway.
Conclusions: MiR-329 may inhibit cell proliferation in human glioma cells through regulating E2F1-mediated
suppression of Akt pathway.
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Glioma multiforme (GBM) is one of the most malignant
brain tumors, with a median survival of ∼ 14 months [1].
Many of its variants demonstrate striking resistance to
even aggressive treatment regimens. Recent advances
have implicated a defined set of oncogenic pathways in
the underlying biology of this tumor group [2]. Among
these crucial signaling networks, the Akt pathway and
E2F1 have emerged as being particularly important in
glioma pathogenesis, which is correlated with poor
prognosis in multiple glioma subtypes [3,4].
MicroRNAs (miRNAs) are a class of short, endogenous,
non-coding RNA molecules that bind with imperfect
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reproduction in any medium, provided the orof target mRNAs, causing translational repression or mes-
sage RNA degradation [5]. Recent studies have shown the
importance of miRNAs in the normal regulation of gene
expression during development and cell proliferation [6].
MiRNAs have also been shown to have critical roles in
tumor biology [7-9], thus we may establish them as a
relatively new and important class of oncogenes and
tumor suppressor genes [10]. Aberrant expression of these
miRNAs has been implicated in tumor growth and
carcinogenesis.
MiR-329 is located on 14q32.31. The miRNA expressing
profile of glioma samples and cell lines suggested that
miR-329 is one of down-regulated miRNAs [11]. However,
the function and molecular mechanism of miR-329 in
determining the malignant phenotype of human glioma
are elusive. In this study, we aimed to determine the role
of miR-329 in determining the proliferation of glioma cells
and study the regulatory mechanism of miR-329 in gliomad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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miR-329 and down-expressing miR-329 in glioma cells
and screened expressing levels of miR-329 and E2F1 in
a group of glioma cells. E2F1 was identified as a signifi-
cant target of miR-329 by luciferase assays, miR-329
was able to induce the G1/S arrest and inhibit prolifera-
tion of glioma cells through E2F1-mediated suppression
of Akt pathway. So miR-329 may act as the role of
tumor suppressor in glioma cells.
Methods
Ethics statement
For the use of clinical materials for research purposes,
prior patients’ consent and approval were obtained from
the General Hospital of Beijing Military Command of
PLA.
Clinical specimens
Glioma tissues were obtained from therapeutic proce-
dures performed as routine clinical management at our
institution. Tissue samples were resected during surgery
and immediately frozen in liquid nitrogen for subse-
quent total RNA extraction. A total of 9 glioma (GBM)
and 3 nonneoplastic brain specimens were included in
our study.
Cell Culture
Glioma cell lines, including A172, LN340, U118MG,
LN464, SNB19, LN18, T98G, and U251MG were grown
in DMEM medium (Invitrogen, Carlsbad, CA,USA)
supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA,USA) and 1% penicillin/streptomycin.
Cells were maintained in a humidified atmosphere at
37°C with 5% CO2.
Construction of the 3′-UTR-luciferase plasmid and
reporter assays
The E2F1 3′-UTR target site was amplified by PCR using
the primers Fwd-5′-CATACTAGTTTCCAGAGATGC
TCACCTTGT-3′ and Rev-5′- CTTAAGCTTAAGACA
GAAGTGCTCTCACCGTC-3′ and cloned downstream
of the luciferase gene in the pGL3-Report luciferase vector
(Ambion, Austin, TX, USA). This vector was sequenced
and named pGL3-E2F1-3′UTR. Reporter assay was
performed at 48 h after transfection using the BriteLite
plus reporter gene assay system (Perkin Elmer, Shelton,
CT, USA).
Reagents, antibodies and expression constructs
The candidate pre-miRNA-329 of double-stranded oligo-
nucleotides was generated for cloning into the pcDNA6.2-
GW/ EmGFP vector (Invitrogen, Carlsbad, CA, USA).
The plasmid was sequenced and named pcDNA6.2-
GW/EmGFP/ miR-329 (pre-miR-329). pcDNA6.2-GW/±EmGFP-miR-neg control plasmid (negative control miR)
contained an insert that could be processed into mature
miRNA but not to target any known vertebrate gene.
The anti-miR molecules were purchased from Ambion
(Austin, TX, USA). Full-length E2F1 expression vector
in the mammalian expression vector, pCMV-SPORT6,
was purchased from Open Biosystems (Huntsville, AL,
USA). The control plasmid, pCMVSPORT6, was gene-
rated by excising the E2F1 insert through restriction
digestion. Antibodies specific for Akt, phospho-AktSer473,
p21 and cyclin D1 were purchased from Cell Signaling
Technology (Beverly, MA, USA). The anti-E2F1 anti-
body was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Akt inhibitor IV was purchased
from Calbiochem (EMD Chemicals Inc, San Diego, CA,
USA). SiE2F1#1 and SiE2F1#2 were from invitrogen
(Invitrogen, Carlsbad, CA, USA). The vectors pBABE-
E2F1 overexpressing E2F1 and pBABE-E2F1-3′UTR in-
cluding miR-329 3′UTR binding site were constructed.
Quantitative RT–PCR assays for mature miRNA
The reverse transcription reactions of cell lines or human
glioma specimens were performed in a reaction containing
50 ng small RNA. Amplification and detection of specific
products were performed with the Roche LightCycler
detection system with the cycle profile according to the
mirVana qRT–PCR miRNA Detection Kit (Ambion,
Austin, TX, USA ). The relative gene expression was cal-
culated by comparing the cycle times for each target PCR.
The target PCR Ct values were normalized by subtracting
the internal control of 5S rRNA Ct value.
3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium
bromide (MTT) assay
Cells, seeded on 96-well plates, were stained at indicated
time point with 100 μL sterile MTT dye (0.5 mg/ml,
Sigma, St. Louis, MO, USA) for 4 h at 37°C, followed by
removal of the culture medium and addition of 150 μL
of dimethyl sulphoxide (DMSO) (Sigma, St. Louis, MO,
USA). The absorbance was measured at 570 nm, with
655 nm as the reference wavelength. All experiments
were performed in triplicates.
Anchorage-independent growth ability assay
Five hundred cells were trypsinized and suspended in
2 ml complete medium plus 0.3% agar (Sigma, St Louis,
MO, USA). The agar–cell mixture was plated on top of
a bottom layer with 1% complete medium agar mixture.
After 10 days, viable colonies that contained more than
50 cells or were larger than 0.1 mm were counted.
Colony size was measured with an ocular micrometer
and colonies greater than 0.1 mm in diameter were
counted. The experiment was performed for three inde-
pendently times for each cell line.
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Cells were plated on 6-well plates (0.5 × 103 cells per plate)
and cultured for 10 days. The colonies were stained with
1.0% crystal violet for 30s after fixation with 10% formal-
dehyde for 5 min.Bromodeoxyuridine labeling and immunofluorescence
Cells grown on coverslips (Fisher, Houston, TX, USA)
were incubated with bromodeoxyuridine (BrdUrd) for
1 h and stained with anti-BrdUrd antibody (Upstate,
Temecula, CA, USA) according to the manufacturer’s
instruction. Gray level images were acquired under a
laser scanning microscope (Axioskop 2 plus, Carl Zeiss
Co. Ltd., Jena, Germany).Luciferase assays
Cells (4×104) were seeded in triplicates in 24-well
plates and allowed to settle for 24 h. The miR-329
mimics, the miR-329-mut, and anti-miR-329 inhibitor
purchased from RiboBio (RiboBio Co.Ltd, Guangzhou,
Guangdong) were respectively transfected into glioma
cells using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) with 100 ng of pGL3-E2F1-3′
UTR, plus 10 ng of pRL-TK renilla plasmid (Promega,
Madison, WI, USA) according to the manufacturer’s
recommendation. Luciferase and renilla signals were mea-
sured 48 h after transfection using the Dual Luciferase
Reporter Assay Kit (Promega, Madison, WI, USA) ac-
cording to a protocol provided by the manufacturer.
Three independent experiments were performed and the
data are presented as the mean + SD.Figure 1 Expression analysis of miR-329 in glioma cell lines and gliom
nonneoplastic brain specimens and primary glioma tissues of nine individu
normal human astrocytes (NHA) and glioma cell lines (including A172, LN3
miR-329 expression was normalized by U6 expression. Each bar represents
blotting analysis of E2F1 in primary normal human astrocytes (NHA) and gl
T98G, and U251MG), β-actin served as the loading control.Flow cytometry analysis
All cells in a culture dish were harvested by trypsinization,
washed in ice-cold PBS, and fixed in 80% ice-cold ethanol
in PBS. Before staining, the cells were spun down in a
cooled centrifuge and resuspended in the cold. Bovine
pancreatic RNAase (Sigma, St. Louis, MO, USA) was
added at a final concentration of 2 mg/mL, and cells were
incubated at 37°C for 30 min, followed by incubation in
20 mg/mL of propidium iodide (Sigma, St. Louis, MO,
USA) for 20 min at room temperature. 50,000 cells
were analyzed on a flow cytometer (FACSCalibur; BD
Biosciences).
Statistical analysis
The Student’s t -test was used to evaluate the significant
difference of two groups of data in all the pertinent
experiments. A P value < 0.05 (using a two-tailed paired
t test) was thought to be significantly different for two
groups of data.
Results
Downregulation of miR-329 in glioma
First, we examined miR-329 expression in GBM cell lines.
Real-time RT-PCR was performed on a panel of 8 human
GBM cell lines and primary normal human astrocytes.
MiR-329 expression of each cell line was compared to the
average expression level of primary normal human astro-
cytes (NHA). As shown in Figure 1B, miR-329 expression
levels of all cell lines were lower than that of NHA, while
expression levels of E2F1 in the cell lines were higher
(Figure 1C). Downregulation of miR-329 was also found
in clinical samples compared with nonneoplastic brain
specimens (Figure 1A).a tissues. A) Real-time PCR analysis of miR-329 expression in three
al patients. B) Real-time PCR analysis of miR-329 expression in primary
40, U118MG, LN464, SNB19, LN18, T98G, and U251MG). The average
the mean of three independent experiments. * P < 0.05. C) Western
ioma cell lines (including A172, LN340, U118MG, LN464, SNB19, LN18,
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glioma
To explore the role of miR-329 downregulation in the
development and progression of glioma, we examined itsFigure 2 Upregulation of miR-329 inhibits the cell proliferation in glio
cell growth of glioma cell lines of T98G and LN18. B) Representative micro
colonies. C) Upregulation of miR-329 inhibited glioma cell tumorigenicity a
Representative micrographs (up) and quantification of colonies that were la
(left) and quantification of BrdU incorporating-cells after transfection with m
experiments. E) Flow cytometric analysis of the indicated glioma cells trans
independent experiments. * P < 0.05.effect on cell proliferation. A MTT assay showed that
miR-329 upregulation significantly inhibited the prolife-
ration rate of LN18 and T98G glioma cells (Figure 2A),
and this was further confirmed by a colony formationma. A) MTT assays revealed that upregulation of miR-329 inhibited
graphs (left) and quantification (right) of crystal violet stained cell
s determined by the anchorage-independent growth assay.
rger than 0.1 mm (down) were scored. D) Representative micrographs
iR-329 or NC. Each bar represents the mean of three independent
fected with NC or miR-329. Each bar represents the mean of three
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expression of miR-329 in LN18 and T98G glioma cells
drastically inhibited their anchorage-independent growth
ability (Figure 2C), as shown by decreased colony num-
bers and sizes, these results suggested that miR-329
upregulation inhibits glioma cell tumorigenicity in vitro.
Using a BrdU incorporation assay, we found that the
percentage of cells in S phase was dramatically de-
creased in miR-329-overexpressing LN18 (12.25%) and
T98G (13.43%) cells compared with control cells (LN18
cells, 27.25%; T98G cells, 28.43%; Figure 2D). Similarly,
the result of flow cytometry showed that miR-329
overexpression decreased the percentage of cells in S
phase and significantly increased the percentage of cells
in G1/G0 (Figure 2E). Collectively, our results suggest
that miR-329 may induce the G1/S arrest and inhibit
cell proliferation of glioma.
MiR-329 inhibition increases cell proliferation in glioma
We further examined the effect of miR-329 inhibition
on cell proliferation in glioma. Consistent with above
mentioned results, MTT and colony formation assays
showed that miR-329 suppression dramatically increased
the growth rate of both LN18 and T98G glioma cells as
compared with that of control cells transfected with
negative control (NC) (Figures 3A and 3B). In addition,
the anchorage-independent growth ability of LN18 and
T98G glioma cells was significantly increased in re-
sponse to miR-329 inhibitor (Figure 3C). Furthermore,
we found that transfection of the miR-329 inhibitor
drastically increased the percentage of cells in the S peak
but decreased the percentage of cells in the G0/G1 peak
(Figures 3D and 3E).These results suggested that the
proliferative effect of inhibiting miR-329 in glioma cells
may occur through regulation of G1/S transition.
MiR-329 directly targets E2F1 in glioma cells
Analysis with the use of two publicly available algorithms
(TargetScan and miRanda), we found that E2F1 mRNA is
theoretically the target gene of miR-329 (Figure 4A). Im-
portantly, western blotting analysis showed that ectopic
expression of miR-329 dramatically decreased, but inhi-
bition of miR-329 increased E2F1 protein expression in
both LN18 and T98G glioma cells (Figure 4B). The
pBABE-E2F1 overexpressing E2F1and pBABE-E2F1-3′
UTR were respectively transfected into glioma cells with
miR-329 mimic expressing using the Lipofectamine 2000
reagent. The result of colony formation assay showed
overexpressing E2F1 significantly increased the prolifera-
tion rate of LN18 and T98G glioma cells compared with
that cells expressing E2F1-3′UTR (Figure 5A), the res-
cuing experiment further confirmed that the inhibitory
role of miR-329 in glioma cells may be mediated by E2F1.
To examine whether miR-329 downregulation of E2F1was mediated by the 3′-untranslated region (3′UTR) of
E2F1, we subcloned the E2F1 3′UTR fragment, containing
the miR-329 binding site, into pEGFP-C1 and pGL3 dual
luciferase reporter vectors. As shown in Figure 4C, over-
expressing miR-329 only decreased expression of a GFP
vector containing the E2F1 3′UTR, but had no effect on
GFP-γ-tubulin expression, the result suggested that miR-
329 specifically affected the 3′UTR of E2F1. To validate
that miR-329 can directly bind to and regulate the levels
of E2F1 mRNA through the predicted binding sites, a
mutant version of the reporter (pGL3–E2F1-3′UTR-mut
plasmids) and altering bases in the putative miR-329 bind-
ing sites (miR-329 mut) were used in luciferase reporter
assay. The consistent and dose-dependent reduction of
luciferase activity was observed following miR-329 trans-
fection in both glioma cells, the reporter assay revealed
that the repressive effect of miR-329 on the luciferase ac-
tivity of E2F1 3′UTR was abolished by miR-329 inhibitor
but did not have the effect in the miR-329 mut group
(Figure 4D). The overexpression of miR-329 also effi-
ciently reduced the expression of the luciferase reporter in
the pGL3–E2F1-3′UTR group but did not have the effect
in the pGL3–E2F1-3′UTR-mut group (Figure 4E). Col-
lectively, these results demonstrate that E2F1 is a bona
fide target of miR-329.
MiR-329 inhibites the Akt pathway
Several studies have shown the importance of the Akt
kinase and mitogen-activated protein kinase (MAPK) sig-
naling pathways in regulating cell growth, survival and
apoptosis. Such as Akt, p21 and cyclin D1, which were im-
portant in signal transduction and regulating cell cycle.
Consistent with above mentioned results, miR-329 is
found to significantly decrease the phosphorylation levels
of intracellular kinases Akt, and upregulate the expression
of p21 in miR-329-overexpressing cells, while pAkt phos-
phorylation was increased and the expression of p21was
inhibited in the miR-329-inhibited cells. Interestingly, the
protein level of cyclin D1, a CDK regulator important for
regulating the G1/S transition, was downregulated in
LN18 and T98G glioma cells transfected with miR-329
mimic, but increased in the cells transfected with miR-329
inhibitor, compared with control cells (Figure 4B).
E2F1 overexpression in glioma cells can cause the
phosphorylated level of Akt increase, interfering with
the expression of E2F1 can decrease the phosphorylated
level of Akt (Figure 6A). The levels of Akt phosphory-
lation are decreased by treatment with Akt inhibitor IV,
in which the p21 is significantly increased and cyclin D1
is downregulated (Figure 6B). These results provided
further evidence that miR-329 may negatively regulate
the Akt survival pathway through E2F1-mediated sup-
pression of Akt phosphorylation and play an important
role in cell proliferation of glioma.
Figure 3 Inhibition of miR-329 promotes cell proliferation in glioma. A) MTT assays revealed that inhibition of miR-329 increased cell
growth of glioma cell lines of T98G and LN18. B) Representative micrographs (left) and quantification (right) of crystal violet stained cell colonies.
C) Inhibition of miR-329 increased the anchorage-independent growth of glioma cells. Representative micrographs (up) and quantification of
colonies that were larger than 0.1 mm (down) were scored. D) Representative micrographs (left) and quantification of BrdU incorporating-cells
after transfection with miR-329 inhibitor or NC. E) Flow cytometric analysis of the indicated glioma cells transfected with NC or miR-329 inhibitor.
Each bar represents the mean of three independent experiments. * P < 0.05.
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The key finding of the current study is that miR-329 ex-
pression was markedly downregulated in glioma cellsand glioma tissues, compared with that in nonneoplastic
brain specimens and primary normal human astrocytes
(NHA). Furthermore, ectopic expression of miR-329
Figure 4 MiR-329 suppresses E2F1 expression and Akt pathway. A) Predicted miR-329 target sequence (blue) in the 3′UTR of E2F1
(E2F1-3′UTR) and positions of the mutated nucleotides (green) in the miR-329 (miR-329 mut). B) Western blotting analysis of E2F1,pAkt, Akt, p21,
cyclinD1 expression in cells transfected with miR-329 or the miR-329 inhibitor, β-actin served as the loading control. C) Western blotting analysis
of GFP expression in the indicated cells, β-actin served as the loading control. D) Luciferase reporter assay of the indicated cells transfected with
the pGL3-E2F1-3′UTR reporter and increasing amounts (10, 50 nM) of miR-329 mimic, miR-329 inhibitor or miR-329 mut oligonucleotides. Bars
represent the mean ± SD of three independent experiments. * P <0.05. E) Luciferase reporter assay of the indicated cells transfected with
pGL3-E2F1-3′UTR or pGL3-E2F1-3′UTR-mut reporter with increasing amounts (10, 50 nM) of miR-329 mimic. * P <0.05.
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growth of glioma, while miR-329 inhibition had the
opposite effect, this point was further confirmed in
Additional file 1: Figure S1. Our results suggested that
anti-proliferation of miR-329 may be related with the-
harrest of G1/S in glioma cells. This is the first study to
show that the oncogene E2F1 is negatively regulated by
miR-329 at the posttranscriptional level through a specific
target site (nt 1655–1661) within the 3′-UTR. E2F1 was
verified as a promising target gene, which is related withG1/S transition. We also showed that miR-329 inhibits
proliferation through E2F1-mediated suppression of Akt
phosphorylation in glioma cells.
E2F1 is a downstream regulator of the Rb pathway,
which is capable of inducing cell proliferation and cell
cycle progression by regulating mTORC1 activity [12-15].
The main molecular regulator of the G1 checkpoint is the
p16/pRb/E2F pathway and abnormalities in every member
of this pathway are present in most of gliomas. However,
others have shown overexpression of E2F1 in gliomas
Figure 5 MiR-329 inhibits cell proliferation through targeting E2F1 3′UTR in glioma. A) Representative micrographs (left) and quantification
(right) of crystal violet stained cell colonies.
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and in vivo [16]. Regardless of p53 status, apoptosis in-
duced by overexpression of E2F1 in glioma cell lines was
further enhanced by treatment with ionizing radiation
[17]. So the function of E2F1 seems to be paradoxical in
glioma.
Recently, a cluster of miRNAs determining the regula-
tion of E2F1 expression has been noticed. For example,
miR-106b, miR-205, miR-15, miR-16, miR-17, miR-20a,
and miR-34a which were located on separated miRNA
clusters can cooperate to inhibit E2F1 translation [18-22].
It has been shown that the low expression of miR-106a in
human glioma specimens is significantly correlated with
high levels of E2F1 protein and high-grade glioma, E2F1 is
a direct functional target of miR-106a, the suppressive ef-
fect of miR-106a on the glioma may result from inhibition
of E2F1 via post-transcriptional regulation [23]. Expres-
sion of several members of miR-17-92 was also signifi-
cantly increased with tumor grade progression. Mir-17-92
inhibition was associated with increased messenger RNA
(mRNA) and/or protein expression of E2F1 [24].
Our results showed that the expression of E2F1 was
regulated by miR-329 and the level of E2F1 protein ex-
pression was inversely correlated with miR-329 expres-
sion in glioma cells. E2F1 functions as an oncogene in
gliomas, the oncogenic function of E2F1 may be mainly
marked in glioma. [25]. The major effect of E2F1 has
been shown to be mediated through the activation of the
Akt-signaling pathway [26].
Akt, a pathway activated in the majority of GBMs, rep-
resents a nodal point in the signaling of malignant
growth. PhosphoAkt expression levels were shown to be
elevated in gliomas in vitro and in vivo [27,28]. Activated
Akt phosphorylates many downstream proteins that can
have a multitude of effects on a cell. Two of Akt’s down-
stream targets are major players in the regulation of cell
cycle entry. GSK-3 promotes cell cycle entry by phos-
phorylating Cyclin D1-Cdk4 complexes, activated AKTphosphorylates GSK-3β to inactivate it [29,30]. This sta-
bilized cyclin D1 will leads to the accumulation of Cyclin
D1 in the cell [29,31]. Cyclin D1 is important for regu-
lating the G1/S transition [32]. A second downstream
target of Akt is MDM2 which is an inhibitor of p53 [33],
so that Akt is free to block p53 activity causing self-
sufficiency in growth signals and limitless replication po-
tential. P21 is one of the downstream effectors p53 and
play the important regulation at G1/S transition and re-
pair damaged DNA [34-36]. Over activation of Akt path-
way (along with several other mutated pathways) can be
involved in the regulation of cell growth and help a nor-
mal astrocyte progress into a malignant glioma.
Our results showed that miR-329 significantly decrease
the expression level of intracellular p-Akt and E2F1 in
miR-329-overexpressing cells. The important downstream
targets of Akt in the regulation at G1/S transition, cyclin
D1 and p21 were respectively downregulated and up-
regulated in miR-329-overexpressing cells. Alternation of
E2F1 may positively affect the expression level of p-Akt.
Furthermore, we also examined whether the Akt inhibitor
can synergize with miR-329 in inhibiting proliferation in
glioma cells, the levels of Akt phosphorylation are de-
creased by treatment with Akt inhibitor IV, in which the
p21 is significantly increased and cyclin D1 is decreased.
Overexpression of E2F1 was shown to be oncogenic and
predisposing cells to neoplastic transformation [12-15].
However, the major effect of E2F1 in conferring numerous
survival advantages has been shown to be mediated
through the activation of the Akt-signaling pathway [26].
In this study, we showed that miR-329 can significantly
decrease the phosphorylation of Akt, miR-329 might
achieve anti-proliferation and induce G1/S transition
through negatively regulating E2F1 expression and
inhibiting Akt pathway at least in part. Qur analysis
revealed that restoring miR-329 expression attenuated
protein level of E2F1 by posttranscription regulation, and
inhibited cell cycle progression in glioma. Targeting to the
Figure 6 E2F1 mediates suppression of Akt pathway. A)
Western blotting analysis of pAkt and Akt after alternation of E2F1
expression. B) Western blotting analysis of pAkt, Akt, p21, cyclinD1
expression after Akt inhibitor IV treatment, β-actin served as the
loading control.
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may be a new therapeutic application to treat glioma
patients in the future.
Conclusions
We have examined the role of miR-329 in biological
behaviors of human glioma cells and its molecular me-
chanism. MiR-329 might suppress the ability of colony
formation and induce G1/S transition in glioma cells. Re-
storing miR-329 expression attenuated protein level of
E2F1 by posttranscription regulation, E2F1 gene was iden-
tified as the target of miR-329. The anti-proliferation ef-
fect of miR-329 partly is related with the inhibition of Akt
pathway mediated E2F1. However, the biological function
of miR-329 in glioma was not be fully elucidated, the role
of it in protection against apoptosis and in cell survival
was still worth further studying. Therefore, miR-329 might
be a potential therapeutic target for glioma that requires
more in-depth analysis.
Additional file
MiR-329 inhibits cell proliferation in SNB19 and
U251 glioma cells. As shown in Figure 1B, miR-329 ex-
pression levels of SNB19 cell lines were lower than that
of other cell lines while expression levels of it in the
U251 cell lines were higher than that of other cell lines.E2F1 expression levels of SNB19 cell lines were higher
than that of other cell lines while expression levels of it in
the U251cell lines were lower (Figure 1C). The result of
MTT showed that the growth speed of U251 is significant
slower than that of SNB19 (Additional file 1: Figure S1A,
S1B). Overexpression of miR-329 in SNB19 cells inhibited
the proliferation ability of cells and the proliferating cells
were significantly decreased, this was confirmed by colony
formation assay and BrdU incorporation assay (Additional
file 1: Figure S1C, S1D, S1E). Inhibition of the miR-329
expression in U251 increased the proliferation ability of
cells and the proliferating cells were significantly in-
creased, this was shown in colony formation assay and
BrdU incorporation assay (Additional file 1: Figure S1C,
S1D, S1E).
Additional file 1: Figure S1 MiR-329 inhibites cell proliferation in
SNB19 and U251 glioma cells. A) Western blotting analysis of E2F1 in
primary normal human astrocytes (NHA) and glioma cell lines (including
A172, LN340, U118MG, LN464, SNB19, LN18, T98G, and U251MG), β-actin
served as the loading control. B, C) MTT assays revealed that the cell
growth of glioma cell lines of SNB19 and U251. D) Quantification of
crystal violet stained cell colonies were scored in glioma cell lines of
SNB19 and U251. E) Quantification of BrdU incorporating-cells after
transfection with miR-329, miR-329 inhibitor or NC. Each bar represents
the mean of three independent experiments in glioma cell lines of
SNB19 and U251.Abbreviations
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sulfate polyacrylamide gel electrophoresis; UTR: Untranslated region. MTT,
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